author-photo

Jin Lu

Peking University

119

Papers

2380

Citations

Citation Trend

Filter By

Papers (82) Sort By

Journal Conference Others

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab-based therapy.

2021 Clinical and translational medicine
Show All
- Source
- Cite
- Save
Citations (0)
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.

2021 Future Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: phase 3 LEPUS (MMY3009) study

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Kimura's disease: clinical characteristics, management and outcome of 20 cases from China.

2021 Clinical and Experimental Rheumatology
Show All
- Source
- Cite
- Save
Citations (0)
Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Prediction of postpartum hemorrhage in pregnant women with immune thrombocytopenia: Development and validation of the MONITOR model in a nationwide multicenter study.

2021 American Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (0)
Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

2020 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

2020 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Fluorescence in situ hybridisation combined with CD138 immunomagnetic sorting is effective to identify cytogenetic abnormalities which play significant prognostic roles in Chinese AL amyloidosis patients

2020 Amyloid
Show All
- Source
- Cite
- Save
Citations (0)